1. Home
  2. BARK vs AVIR Comparison

BARK vs AVIR Comparison

Compare BARK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BARK Inc.

BARK

BARK Inc.

HOLD

Current Price

$0.63

Market Cap

115.2M

ML Signal

HOLD

Logo Atea Pharmaceuticals Inc.

AVIR

Atea Pharmaceuticals Inc.

HOLD

Current Price

$3.13

Market Cap

236.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BARK
AVIR
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.2M
236.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BARK
AVIR
Price
$0.63
$3.13
Analyst Decision
Strong Buy
Hold
Analyst Count
3
1
Target Price
$2.50
$6.00
AVG Volume (30 Days)
690.5K
364.5K
Earning Date
02-04-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$451,690,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$2.46
52 Week High
$2.32
$4.02

Technical Indicators

Market Signals
Indicator
BARK
AVIR
Relative Strength Index (RSI) 37.23 49.61
Support Level $0.61 $3.11
Resistance Level $0.67 $3.27
Average True Range (ATR) 0.03 0.10
MACD 0.00 0.01
Stochastic Oscillator 17.95 52.63

Price Performance

Historical Comparison
BARK
AVIR

About BARK BARK Inc.

BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: